#None #FarmaMondo #Zemcelpro #ExCellThera

ExCellThera Inc. Expands Zemcelpro Availability in New Markets

ExCellThera Inc., a leading name in blood stem cell technology, has recently made significant strides in its global expansion efforts. Through a strategic partnership with FarmaMondo, the company will distribute its innovative treatment, Zemcelpro® (dorocubicel), also known as UM171 cell therapy, in Argentina, Hong Kong, and Singapore. This collaborative effort aims to facilitate early access to life-saving therapies in regions where such treatments may not be readily available.

Zemcelpro® is a cutting-edge product designed for the transplant of cryopreserved hematopoietic stem cells. This unique therapy consists of two cellular components: CD34+ cells expanded using the UM171 method (dorocubicel) and non-expanded CD34- cells, both sourced from the same umbilical cord blood unit. The therapy is indicated for adult patients suffering from hematological malignancies who require allogeneic hematopoietic stem cell transplants due to the unavailability of compatible donors. Recently, it received conditional marketing authorization from the European Commission, underscoring its potential as a breakthrough treatment for patients in urgent need.

As part of the agreement, FarmaMondo will leverage its expertise in regulatory compliance and market access to ensure smooth distribution processes across the designated territories. This initiative is expected to aid in providing Zemcelpro® to patients who qualify, utilizing applicable early access programs to navigate complex healthcare landscapes. David Millette, CEO of Cordex, a subsidiary of ExCellThera, expressed enthusiasm for the partnership, noting that it aligns with their ongoing strategy to increase access to this vital therapy. He emphasized the persistent interest from healthcare providers and stakeholders in innovative treatments for blood cancers and stem cell transplants.

In addition to its immediate goals, the collaboration represents a broader mission to enhance patient access to advanced therapeutics, especially in underserved markets. Yaron Spigel, CEO of FarmaMondo, highlighted the importance of their joint efforts, asserting their commitment to delivering specialized medications in regions where access might be otherwise challenging.

Looking forward, ExCellThera and FarmaMondo plan to continue exploring avenues for significantly improving patient access to Zemcelpro across Europe and other international markets through strategic partnerships. With more than 120 patients involved in clinical evaluations in the U.S., Canada, and Europe, Zemcelpro has garnered various designations, including orphan drug status from the FDA and the EMA, emphasizing its novel therapeutic approach and commitment to treating high-risk patients.

As research and regulatory pathways progress, the companies are optimistic about expanding Zemcelpro’s indications, including trials targeting pediatric populations and patients with non-malignant hematologic disorders. The ultimate goal remains enhancing the therapeutic landscape and addressing pressing medical needs in hematological oncology.

For detailed product information, including warnings and precautions associated with Zemcelpro®, stakeholders are encouraged to consult the European product characteristics summary available at zemcelpro.com.

In summary, the collaboration between ExCellThera and FarmaMondo opens a new chapter for Zemcelpro, marking an essential step in ensuring access to innovative, life-changing treatments for those battling serious hematological conditions. The trajectory of this partnership illustrates the ongoing commitment of both companies to serve patients worldwide effectively.

About ExCellThera

ExCellThera is renowned for its advancements in stem cell therapies; its exclusive Enhance™ platform supports the cultivation and metabolic optimization of hematopoietic stem cells. This technology aims to elevate the quantity and quality of therapeutic stem cell doses, benefiting patients in need of these crucial treatments.

About FarmaMondo

FarmaMondo specializes in the distribution of innovative medical treatments in emerging markets, navigating complex regulatory environments to deliver essential therapies where they're most needed. Their efforts focus on establishing local partnerships to improve patient access and ensure compliance with the established healthcare standards.